VHH Antibodies: Enabling New Frontiers in Biologic Drug Design

 

Introduction

Antibodies are cornerstone molecules of adaptive immunity and have become central to therapeutic and diagnostic biotechnology. Classical antibodies (e.g., human IgG) comprise two heavy and two light chains, forming a complex quaternary structure that delivers high-affinity, high-specificity binding to antigens. However, in the 1990s, researchers discovered that members of the Camelidae family (camels, llamas, alpacas) naturally produce an unusual class of antibodies, heavy-chain-only antibodies (HCAbs), which lack the light chain entirely. The antigen-binding variable region of these HCAbs, the single V-domain, was termed VHH (also referred to in some cases as a Nanobody). Remarkably, VHH domains alone retain full antigen-binding capability while being vastly smaller and simpler than conventional antibodies. This discovery has opened a rich new field of “single-domain antibody” engineering, with important implications for research, diagnostics, and therapeutics. In this article, we review the molecular nature of VHHs, how they are generated, why they offer advantages across drug discovery, what makes them promising for therapeutic use (especially as multi-component biologics), and finally survey some VHH-based molecules currently in clinical trials.

VHH Antibodies: Origin and Molecular Structure

VHH antibodies originate from camelid heavy-chain–only antibodies (HCAbs), naturally produced in camelids such as llamas, alpacas, and camels. Unlike conventional IgG, these HCAbs lack light (L) chains, so antigen binding relies solely on a single heavy-chain variable domain, the VHH. Because of their single-domain nature, VHHs are much smaller, roughly 12–15 kDa, compared to ~150 kDa for a full IgG. Structurally, a VHH domain adopts the immunoglobulin variable (IgV) fold, a β-sandwich composed of two antiparallel β-sheets, similar to a conventional VH domain. The complementarity-determining regions (CDRs), especially CDR3 differ: VHHs generally have longer, more flexible CDR3 loops than conventional VH domains, and often harbor non-canonical disulfide bonds.  The antigen-binding paratope is formed entirely by the three CDRs of the VHH, in contrast to conventional antibodies where six CDRs (three from VH, three from VL) contribute.   Fig. 1 Heavy chain antibodies are composed of two heavy chains. The target-binding module is composed of a single VHH domain. Conventional antibodies are composed of two heavy and two light chains. The target-binding module is composed of two non-covalently associated variable domains VH and VL. In intact antibodies, the proper orientation of these is stabilized by the disulfide-linked CL and CH1 domains. Front. Immunol. 8:1603. doi: 10.3389/fimmu.2017.01603 Definitions:

• Light chain, Heavy chain. The two types of polypeptide chains form a conventional antibody: two identical light chains and two identical heavy chains, with heavy chains determining isotype and overall structure while both contribute to antigen binding.
• Variable domain, VH and VL. The N-terminal domains of the heavy (VH) and light (VL) chains that contain sequence diversity and form the antigen-binding site through their combined three-dimensional interface.
• CDR loops. Three hypervariable loop regions within each variable domain (CDR1–3) that provide most of the antibody’s antigen-binding specificity and affinity.
• The specific surface region of an antibody (formed mainly by the VH and VL CDRs) that directly contacts and binds the antigen’s epitope.

 Antibody Libraries and Screening for Potent VHHs

To harness VHHs for research or therapy, scientists rely on antibody libraries from which potent VHHs can be selected. Broadly, there are three types of VHH libraries used for screening:

• Immune libraries: generated from camelids (e.g., llamas, alpacas) immunized with a given antigen.
• Naïve libraries: derived from non-immunized camelid B cells; reflect natural repertoire diversity.
• Synthetic or semi-synthetic libraries: engineered in vitro by randomizing CDRs or framework regions to maximize diversity.

Among these, immune libraries typically yield the highest-affinity binders because they derive from B cells that have undergone somatic hypermutation and affinity maturation in response to immunization.   Table 1. Comparison of VHH and conventional mAbs.

Feature	VHH (single-domain)	Conventional monoclonal antibody
Molecular weight	~ 12–15 kDa	~ 150 kDa (two heavy + two light chains)
Domain composition	Single VH-derived variable domain (VHH) only	Two heavy + two light chains; antigen binding via VH + VL variable domains
Paratope composition	Three CDRs (CDR1, CDR2, CDR3) on VHH; no light chain CDRs	Six CDRs (three from VH, three from VL)
Binding surface / epitope access	Elongated, flexible CDR3 often enabling access to recessed or cryptic epitopes	Paratope often flatter or more constrained, less suited to highly recessed epitopes
Stability, solubility	High solubility, resistance to aggregation; stable under heat, pH extremes, proteases	More prone to aggregation when misfolded; less stable under extreme conditions; require proper pairing/folding of heavy and light chains
Expression & production	Single gene; easily expressed in bacterial/yeast/mammalian systems; high yield; no light chain pairing needed	Requires expression of two (or four) polypeptide chains; complex folding; often requires mammalian expression systems for correct assembly

  VHH domains represent a minimalistic yet fully functional antigen-binding module: small, stable, and capable of binding in ways that conventional antibodies cannot. Typical Process for Immune Library Generation and Screening.

1. Immunization: A camelid (e.g., alpaca, llama) is immunized with the target antigen (protein, viral protein, etc.). For example, in a study against SARS-CoV-2, an alpaca was immunized with purified spike RBD over a 50-day schedule.
2. Sampling B cells: After immunization, peripheral blood mononuclear cells (PBMCs) are harvested; B cells are isolated. The mRNA encoding heavy-chain–only antibodies is extracted, and cDNA synthesized.
3. Library generation: Using PCR, the VHH-encoding sequences are amplified (often using primers specific for the camelid VHH framework), then cloned into a phage display vector (or other display system) to build a VHH phage library. This preserves the full immunized repertoire.
4. Screening (panning): The phage library is subject to rounds of panning (binding to immobilized antigen, washing, elution) to enrich for phage displaying VHHs that bind the antigen. Usually multiple rounds yield enrichment of high-affinity clones. For instance, in the alpaca immunization against SARS-CoV-2 spike, two rounds of panning were used before screening by ELISA.
5. Clonal screening and characterization: Individual clones from the enriched pool are expressed (often in bacteria or yeast), purified, and assayed (e.g., by ELISA, surface plasmon resonance, neutralization assays) to assess binding affinity, specificity, cross-reactivity, and functional activity. High-affinity clones are sequenced (to determine their unique CDR3 sequences) and further characterized.
6. Affinity maturation: For therapeutic applications, promising VHH clones may be subjected to affinity maturation (through error-prone PCR, chain shuffling, rational mutagenesis) to improve binding kinetics. They may also be humanized (modifying sequences to reduce immunogenicity) and reformatted (e.g., as Fc-fusions, multivalent constructs).
7. Humanization: Therapeutic VHH antibodies humanization is often required to reduce immunogenicity. Whether it’s needed depends on the extent of natural human-like features already present in the VHH, the route/frequency of administration, and the therapeutic context.  VHHs are naturally more “human-like” than full camelid IgG. Many unmodified VHHs have already been shown to have low intrinsic immunogenicity in preclinical models.

  Naïve and synthetic libraries follow similar display / screening workflows, though without prior antigen-driven affinity maturation. Synthetic libraries can expand sequence/structural diversity beyond what is present in the natural repertoire, at the cost of potentially lower initial affinities that may require more engineering. An important recent development: large-scale VHH datasets derived from immunized alpacas (e.g., against IL-6) have become available, facilitating computational and machine-learning approaches for predicting antigen–VHH interactions and guiding design/optimization efforts.

Advantages of VHH Antibodies for Drug Discovery

VHH antibodies offer a broad range of advantages that make them attractive across nearly every stage of a biologic drug discovery pipeline, from initial target engagement through lead optimization and manufacturing. Their simplicity and scalability of production stem from the fact that each VHH is encoded by a single gene and composed of a single polypeptide domain. As a result, VHH can be efficiently expressed in prokaryotic hosts such as E. coli, in yeast, or in streamlined mammalian systems. These features enable high expression yields, straightforward cloning workflows, and reduced manufacturing complexity. VHHs also possess robust biophysical properties. They are typically highly soluble, resist aggregation, and maintain stability under harsh environmental conditions, including elevated temperatures, extreme pH, and proteolytic exposure. Such resilience makes them easier to handle, formulate, and store, while also supporting the development of diverse delivery routes such as inhaled, oral, or subcutaneous administration. A major functional advantage of VHH antibodies is their ability to access recessed epitopes. Their compact single-domain architecture, combined with characteristically elongated CDR3 loops, enables them to insert into narrow clefts, enzyme active sites, and other sterically challenging surfaces that are often inaccessible to conventional antibodies. This expands the therapeutic “druggable epitope” space beyond what larger monoclonal antibodies can typically reach. Furthermore, VHH antibodies offer exceptional flexibility and modularity in molecular design. They can be readily reformatted into Fc fusions, multimeric constructs, bispecific or trispecific antibodies, antibody–drug conjugates, immunocytokines, and many other architectures. This modularity allows VHHs to support diverse therapeutic strategies, from enhanced effector functions to targeted delivery of payloads. Because of this unique combination of manufacturability, stability, design flexibility, and epitope reach, VHHs are increasingly recognized not only as powerful research tools but also as a core modality for next-generation biologics. They offer potential advantages in tissue penetration, production efficiency, and the creation of novel mechanisms of action.

Therapeutic Advantages of VHH Antibodies

Beyond their utility in drug discovery, VHH antibodies possess intrinsic biophysical and functional properties that make them particularly advantageous as therapeutic agents. Their exceptionally small size and compact structure enable superior tissue penetration and favorable biodistribution, allowing VHHs to reach dense, tightly packed, or poorly vascularized regions such as solid tumors or cryptic viral epitopes more effectively than conventional antibodies. Their high thermal, pH, and protease stability provides remarkable formulation and delivery flexibility, supporting routes of administration beyond intravenous infusion, including inhalation for respiratory diseases, subcutaneous injection, and potentially even oral or enteral delivery. VHHs also exhibit low intrinsic immunogenicity due to their substantial sequence homology, over 80%, with human VH regions, particularly members of the human VH3 subgroup, which facilitates efficient humanization and reduces immunogenicity risk. The pharmacokinetic behavior of VHHs can be tuned to therapeutic need: unmodified monomeric VHHs undergo rapid renal clearance, which is beneficial for imaging or diagnostic applications where low background signal is essential, or for therapeutics requiring a short half-life. Conversely, extended systemic exposure can be achieved through reformatting strategies such as Fc-fusion, PEGylation, or multimerization. VHHs maintain high-affinity and highly specific binding despite their small size. They routinely reach nanomolar or even sub nanomolar affinities, especially when engineered into multivalent formats, and their distinctive paratope geometry allows them to recognize epitopes that are inaccessible to conventional monoclonal antibodies. Collectively, these attributes make VHH antibodies well suited for therapeutic applications across virology, oncology, autoimmunity, and inflammatory diseases, particularly where deep tissue penetration, access to cryptic epitopes, or compatibility with nonstandard delivery routes confers a clinical advantage.

VHHs in Multi-Component Therapeutics: Bispecifics, Trispecifics, ADCs, Immunocytokines

One of the most exciting aspects of VHH technology is its modularity: VHH domains can be concatenated, fused, or modified to create multi-component biologics that would be difficult to build with conventional antibodies. Some advantages include:

• Bispecific or trispecific antibodies: Because each VHH is small and encoded by a single gene, multiple VHHs directed against different epitopes or targets can be fused together to generate bispecific or trispecific constructs. This enables simultaneous engagement of, for example, a tumor antigen and an immune effector, or two different epitopes on the same antigen to increase avidity or block multiple functional sites. The lack of light chains simplifies engineering, avoids heavy-light chain mispairing (a common problem in bispecific IgG design), and reduces complexity.
• Antibody–drug conjugates (ADCs): VHHs can serve as targeting moieties in ADCs: their small size improves tumor penetration, and the simple single-domain format makes conjugation chemistry more straightforward. Their stability helps withstand the chemical conditions often used in conjugation or linker design.
• Immunocytokines / fusion proteins: VHHs can be fused to cytokines, enzymes, toxins, or other payloads to deliver them specifically to a target (e.g., tumor, inflamed tissue), benefiting from VHH’s targeting specificity, tissue penetration, and stability.
• Multivalency / avidity enhancement: By linking several VHHs (identical or distinct), one can achieve very high overall binding strength (avidity), potentially reaching picomolar apparent affinities even if monovalent affinities are nanomolar.

  Overall, the structural simplicity and modularity of VHHs greatly expand the design space for next-generation biologics beyond classical monoclonal antibodies.

VHH-based Antibodies in Clinical Trials

VHH antibodies have progressed from experimental molecular scaffolds to a clinically validated therapeutic class, with an expanding pipeline that includes agents for autoimmune, inflammatory, infectious, and oncologic indications. Based on current ClinicalTrials.gov entries and recent landscape analyses, approximately 30–50 VHH-based candidates are in U.S. clinical trials, depending on whether imaging agents and VHH-engineered cell therapies are included. Among the most advanced programs, a bivalent VHH targeting the A1 domain of von Willebrand factor, has demonstrated accelerated platelet normalization and reduced thrombotic thrombocytopenic purpura–related complications in Phase II/III studies, leading to regulatory approval. Similarly, a VHH-based dual-specific inhibitor of complement component C5 with an albumin-binding extension for half-life enhancement, recently met the primary endpoint in a Phase III study in generalized myasthenia gravis, producing clinically meaningful improvements.  Together, these developments illustrate the maturation of VHH antibodies into a robust therapeutic platform with increasing clinical impact and a strong trajectory for future expansion.

Conclusion

VHH antibodies, single-domain, camelid-derived variable heavy chain domains, represent a transformative evolution in antibody technology. Their compact size, structural simplicity, high solubility, thermal and chemical stability, and ability to bind recessed or cryptic epitopes make them exceptionally versatile. By building libraries (immune, naïve, or synthetic) and applying display and screening technologies, researchers can rapidly identify high-affinity, specific VHH binders. These binders can then be engineered, humanized, and formatted into diverse therapeutic architectures such as: Fc-fusions, bispecific/trispecific antibodies, ADCs, and immunocytokines.  The advantages of VHHs, manufacturability, robustness, tissue penetration, and epitope access, address many of the limitations of conventional monoclonal antibodies. Consequently, VHH-based therapeutics are rapidly advancing through clinical development, with multiple candidates already in Phase 2 trials across autoimmune disease, oncology, and inflammation.  As antibody engineering and biomanufacturing technologies continue to mature, VHHs are poised to become a foundational modality for next-generation biologics, enabling treatments that are more potent, better targeted, easier to manufacture, and suitable for a broader range of diseases and delivery routes than classical antibodies alone allow.   Table 2. Examples of VHH antibodies in Phase 2 Clinical Trials

Molecule	Format / Domains	Targets (antigens)	Special features / Indications
Sonelokimab	VHH‑VHH‑VHH (trivalent nanobody)	IL‑17A, IL‑17F, + binding to human serum albumin	Dual IL‑17A/F blockade + albumin-binding module for extended half-life / tissue penetration. Psoriatic arthritis
V 565	Single-domain VHH	TNF‑α (soluble & transmembrane)	Engineered for protease resistance, oral delivery possible. Inflammatory bowel disease (IBD)
NM 01	VHH nanobody	PD-L1	diagnostic imaging agent
BI 836880	Bispecific nanobody (VHH) + albumin-binding module	VEGF‑A (splice variants) + Ang‑2	Dual anti-angiogenesis (VEGF + Ang-2) + albumin module for half-life extension. metastatic solid tumors

  Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.  

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024. Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline. Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.    

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)

• ADME/Tox
• Molecular Biology
• The Art of Cell Culture
• Exosomes
• Stability Services
• Potency Assay
• Gene Therapy Assays
• Immunotherapy Assays
• Antiviral Therapy Assays
• cGMP
• MLR
• Cell Based Assays
• ELISA
• Flow Cytometry
• Protein
• PCR-qPCR
• Immunoassay
• Radioimmunoassay
• GLP
• Transfection
• Cell Therapy Assays
• Targeted Protein Degradation
• Research to Commercialization